Jennifer Simpson 의 보수는 Panbela Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$38m
Mar 31 2024	n/a	n/a	-US$36m
Dec 31 2023	US$572k	US$527k	-US$34m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$36m
Dec 31 2022	US$694k	US$506k	-US$35m
Sep 30 2022	n/a	n/a	-US$34m
Jun 30 2022	n/a	n/a	-US$31m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$1m	US$477k	-US$10m
Sep 30 2021	n/a	n/a	-US$7m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$2m	US$146k	-US$5m

보상 대 시장: Jennifer 의 총 보상 ($USD 571.92K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Jennifer 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jennifer Simpson (56 yo)

4.2yrs

테뉴어

US$571,921

보상

Dr. Jennifer K. Simpson, Ph.D. M.S.N. C.R.N.P. has been the Chief Executive Officer, President and Director of Panbela Therapeutics, Inc. (formerly known as Sun BioPharma, Inc.) since July 15, 2020. She se...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jennifer Simpson	CEO, President & Director	4.2yrs	US$571.92k	0.00014% $ 2.4
Jeffrey Mathiesen	Vice Chair & Lead Independent Director	9yrs	US$85.14k	0% $ 0
Michael Cullen	Chairman	9yrs	US$76.14k	0.00045% $ 7.6
Jeffrey Jacob	Director	2.3yrs	US$43.63k	0.000020% $ 0.3
Daniel Donovan	Independent Director	2.3yrs	US$56.13k	0.00023% $ 3.9
Arthur Fratamico	Independent Director	4.8yrs	US$52.63k	0% $ 0
Donald Schemel	Independent Director	9yrs	US$61.13k	0.00045% $ 7.6
Tanios Bekaii-Saab	Scientific Advisor	no data	데이터 없음	데이터 없음
Andrew Ko	Scientific Advisor	no data	데이터 없음	데이터 없음
Dusan Kotasek	Scientific Advisor	no data	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: PBLA 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Panbela Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Panbela Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

Independent Director recently bought US$63k worth of stock

Sun Biopharma, Inc. Announces Appointment of Jennifer K. Simpson, Ph.D., as Chief Executive Officer

Recent updates

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Therapeutics, Inc. Announces Nasdaq Files A Form 25 Notification of Removal from Listing

Panbela Therapeutics, Inc. Announces Interim Data Analysis for its Ongoing ASPIRE Trial Pushed to First Quarter of 2025

Panbela Announces Transfer to OTCQB Market

Panbela Therapeutics, Inc. has filed a Follow-on Equity Offering.

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

The Nasdaq Stock Market Notifies Panbela Therapeutics That the Nasdaq Hearings Panel Has Determined to Delist the Company’s Common Stock

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum

Panbela Therapeutics Receives Notice from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(4)

Panbela Therapeutics, Inc. Announces Publication of Clinical Data Titled: Phase 1 Study of High-Dose DFMO, Celecoxib, Cyclophosphamide and Topotecan for Patients with Relapsed Neuroblastoma

Panbela Therapeutics, Inc. Announces second Independent Safety Review of the ASPIRE Registration Clinical Trial

New major risk - Negative shareholders equity

Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves B Cell Function in Type 1 Diabetes

New minor risk - Share price stability

Panbela Therapeutics, Inc. Announces Acceptance of Polyamine Inhibitor Car-T Combination Abstract for Online Publication

New major risk - Revenue and earnings growth

Panbela Therapeutics, Inc. Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Panbela Therapeutics, Inc. Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.510816 million.

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Panbela Announces 1-For-30 Reverse Stock Split Effective June 1, 2023 to Regain Compliance with the Continued Listing Requirements of the Nasdaq Capital Market

Forecast to breakeven in 2025

Panbela Therapeutics Regains Compliance with Nasdaq Listing Standards

Forecast to breakeven in 2025

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.01875 million.

Panbela Therapeutics, Inc. Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF

Panbela Therapeutics, Inc. Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Price target decreased to US$6.00

Panbela Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Panbela Therapeutics Receives a Notification Letter from Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Panbela Therapeutics, Inc. has completed a Follow-on Equity Offering.

Panbela Therapeutics, Inc. Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Therapeutics dips 24% on pricing $6M public offering

Panbela Therapeutics Receives a Letter from The Nasdaq Stock Market LLC Regarding Minimum Stockholders' Equity Requirement

Panbela Therapeutics GAAP EPS of -$1.51

Panbela Therapeutics, Inc. Receives Approval from Australian Human Research Ethics Committee to Expand Global Clinical Trial to Australia

Panbela Therapeutics, Inc. Announces the Publication of Preclinical Data from Studies of SBP-101

Less than half of directors are independent

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) completed the acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Therapeutics, Inc., Annual General Meeting, Jun 08, 2022

Price target increased to US$8.00

Panbela Therapeutics, Inc. (NasdaqCM:PBLA) entered into a definitive agreement to acquire Cancer Prevention Pharmaceuticals, Inc.

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Panbela Presents Clinical Data on Phase 1B Clinical Trial of Sbp-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pda At 2022 Asco Gi Meeting

Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

Panbela Therapeutics, Inc. Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines

Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?

Director Jennifer Simpson has joined 3rd company board

Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth

Panbela Therapeutics to join Russell Microcap Index

Panbela Therapeutics, Inc. Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting

Forecast to breakeven in 2025

We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth

Panbela Therapeutics Inc. Provides Update on Current Clinical Trial: Decision to Hold Administration of SBP-101

New 90-day high: US$4.93

Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1B Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer

New 90-day high: US$4.37

Independent Director recently bought US$63k worth of stock

Sun BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $10.5 million.

Sun Biopharma, Inc. Announces Appointment of Jennifer K. Simpson, Ph.D., as Chief Executive Officer

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령